Seattle Genetics (SGEN -1.9%) is all over the board today after being pelted with news-related...

Seattle Genetics (SGEN -1.9%) is all over the board today after being pelted with news-related issues. Initially, the stock popped after announcing it had struck a new antibody drug conjugate collaboration deal with Bayer (BAYRY.PK) worth up to $520M, only to collapse on reports that it had temporarily halted studies of its Lymphoma drug Adcetris due to safety concerns over reports of pancreatitis.

From other sites
Comments (3)
  • billchristie
    , contributor
    Comments (23) | Send Message
    One STUDY was halted-not STUDIES. Adcetris alongside Chemo in elderly patients in HL. One Patient, one case of pancreatitis.
    25 Jun 2013, 01:32 PM Reply Like
  • Scrying Biotech
    , contributor
    Comments (2853) | Send Message
    The mistake is the design of the trial which should have excluded a follow-up blast of chemotherapy. Adcetris alone would have done the job.
    25 Jun 2013, 02:45 PM Reply Like
  • fafatooey
    , contributor
    Comments (435) | Send Message
    Could be a deal breaker for SGEN.
    25 Jun 2013, 05:22 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs